Nora
Bengoa Vergniory
Principal Investigator
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (1)
2017
-
Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo
Molecular Therapy, Vol. 25, Núm. 10, pp. 2404-2414